Brief: Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
25/07/2024 14:22
July 25 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O :
* MIRUM’S LIVMARLI NOW APPROVED FOR PFIC IN PATIENTS 12
MONTHS AND
OLDER
Source text for Eikon: ID:nBw3wq5gDa
Further company coverage: MIRM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX